Solutions to advance life science

Harvard Bioscience is a global leader in the manufacture and distribution of solutions to advance life science research.  For over 110 years, we have served the changing needs of life scientists in over 100 countries. Our expanding portfolio of brands include instruments for organ and animal research, cell analysis, molecular biology, fluidics, and laboratory consumables.

Learn More.

Solutions to Advance Life Sciences

Laboratory Fluidics

With more than 100 years of success and a proven track record of designing and manufacturing high quality reliable syringe and peristaltic pumps, we have the knowledge to recommend the right pump and accessories to suit any customer’s application.

Learn More

Fluidics

Molecular Analysis

Our line of spectrophotometers, amino acid analyzers and microplate readers are among the most advanced in the world and trusted by scientists, doctors and technicians in hospitals and laboratories worldwide.

Learn More

Fluidics

Cell Analysis

A world leader in electrophysiology, electroporation, cell imaging, and cell fusion, we have the expertise and scientific depth to help our customers select the right tools, as well as the commitment to provide the technical support to help them succeed.

Learn More

Cell-Analysis

Lab Equipment & Supplies

We continue to develop the tools and innovations that are giving scientists the edge they need in this increasingly competitive world. Our expertise and years of experience allows us to provide the best solutions for the most demanding applications.

Learn More

Lab-Supplies

Physiology

World class surgical instruments, anesthesia equipment, temperature control products, physiological monitoring equipment, and cutting edge regenerative medicine products as well as the most comprehensive line of equipment for behavioral research.

Learn More

Physiology

Spotlight

Accumulated Inhaled Aerosol (AIA) with DSI’s Buxco Inhalation System

The Buxco AIA system provides researchers with real-time aerosol amounts inhaled and deposited in subjects’ lungs, a breakthrough improvement over the current delivered dose measurement. By reporting those measures against real-time respiratory endpoints using FinePointe software, researchers can now observe a direct correlation between dose and lung function over time.

 

Integrating exposure and respiratory capabilities, this system delivers precise amounts of various aerosols to multiple subjects in a uniform, and reproducible manner, then measures pulmonary effects from the same platform. This technology and other new advancements in the Harvard Bioscience inhalation platform provide researchers with novel tools to study COVID-19 and advance development in both the discovery of new therapies and the pre-clinical regulatory phases, as solutions progress toward general clinical use.